Assembly committee approves bill restricting biosimilar substitutions

08/23/2013 | California Healthline · Drug Store News

A bill that would require pharmacists to inform prescribers when they substitute a biosimilar drug for a biologic medication was approved by a California Assembly committee. The bill, SB 598, also would prevent the substitution of biosimilars when prescriptions include a "do not substitute" direction.

View Full Article in:

California Healthline · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA